Dual-Targeting Compound Improved Immunotherapy Response in Pancreatic Cancer
A compound targeting both STING and PI3Ky improved immunotherapy response in pancreatic cancer models.
Pancreatic ductal adenocarcinoma is one of the deadliest cancer types, with a five-year survival rate of 13%.
There are only two treatment regimens available with limited efficacy.
Pancreatic cancers do not respond to immunotherapy where the body’s immune system attacks tumor cells.
The effectiveness of these treatments is limited due to immunotherapy resistance.
During this process, myeloid and regulatory B cells of the immune system suppress other immune mechanisms from attacking pancreatic tumors.
A team of researchers from the College of Pharmacy and Rogel Cancer Center at the University of Michigan has developed a new strategy to improve immunotherapy treatments.
Immune resistance in pancreatic cancer is complicated because there are multiple resistance pathways. We wanted to develop a drug molecule that could adaptively stimulate the helpful pathways while inhibiting the harmful ones.” — Duxin Sun, professor of pharmaceutical sciences.
“Immune resistance in pancreatic cancer is complicated because there are multiple resistance pathways,” said Duxin Sun, U-M Professor of Pharmaceutical Sciences.
“We wanted to develop a drug molecule that could adaptively stimulate the helpful pathways while inhibiting the harmful ones.”
Previously, researchers had identified compounds that boost the effectiveness of immunotherapy agents called STING agonists.
STING, or STimulator of Interferon Genes, activates specific parts of the immune system, helping the body fight tumors.
Although STING agonists were able to overcome immunotherapy resistance driven by myeloid cells, they also induced resistance by increasing the number of regulatory B cells.
In the new study, the team found that STING agonists activate myeloid cells independent of the enzyme PI3Kγ but increase the number of regulatory B cells through PI3Kγ.
The researchers showed that in mouse models and human cells derived from patients with pancreatic cancer, using STING agonists and inhibiting PI3Kγ can improve immunotherapy pathways.
Advancing Biomarker Discovery With Liquid Biopsy Research
This webinar explores how liquid biopsy research is advancing biomarker discovery through extracellular vesicle (EV)-associated biomarkers and circulating tumor DNA (ctDNA).View Webinar
Based on this discovery, they developed a dual-targeting compound, SH-273, to simultaneously activate STING and inhibit PI3Kγ.
The drug increased the survival of pancreatic cancer mouse models to 201 days, while most therapeutics do not show any efficacy in these mice that bear the same mutations as human pancreatic cancers.
It also decreased tumor metastasis and invasion in the lungs and was not toxic to the animals.
“It is significant that a treatment has improved survival for such a long time in mice with pancreatic tumors,” Sun said.
“Our findings point to a new therapeutic concept for pancreatic cancer—keeping the immune system’s ‘go’ signals on, while shutting down the B cell brake that fuels resistance.”
The team hopes to advance SH-273 in phase 1 trials and will continue to investigate additional immune mechanisms that can be harnessed to overcome immunotherapy resistance.
Reference: Li C, Ke F, Zhao H, et al. Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancer. Nat Cancer. 2026. doi: 10.1038/s43018-026-01158-7
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
